Navigation Links
Genomma Lab Announces 2009 Earnings Guidance
Date:12/10/2008

MEXICO CITY, Dec. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company, announced today its 2009 earnings guidance. The Company expects to reach organic growth without considering acquisitions in the range of 21% - 22% in net sales and an EBITDA(I) margin in the range of 27% - 28%. These estimates are based on the organic growth of core products (products launched during and before 2007); the full year effect in sales of those products launched during 2008; the growth of Genomma Lab's international operations; as well as the Company's launch program of product line extensions and new brands in new categories and in those in which the Company already participates.

Genomma Lab expects to maintain its strategy of brand acquisitions and, on a timely basis, will inform the market on any completed transaction, as well as the corresponding change to the Company's earnings guidance. As of the close of the third quarter 2008, the Company had a cash balance and equivalents of Ps. 1,073 million that may be used partially or totally for potential brand acquisitions.

Genomma Lab will continue its efforts to increase its share in the Mexican personal care and over-the-counter markets. The value of such markets is approximately Ps. 75 billion(II) and Ps. 19 billion(III), respectively.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB" (Bloomberg: labb.mx).

    Web Site: www.genommalab.com

      (I) EBITDA is defined as Operating Income plus Depreciation and
          Amortization
     (II) Source:  Euromonitor (2006)
    (III) Source:  Datamonitor (2007)

    Investor Relations in Mexico City:
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:
    i-advize Corporate Communications, Inc.
    Tel: (212) 406-3692
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Internacional Acquires UNIGASTROZOL
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
4. WellPoint Announces Appointment of Andrew J. Lang as Senior Vice President of Application Development
5. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
6. Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage
7. Allscripts Announces Expiration of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024
8. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
9. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
10. American Lung Association Announces Support of Pickens Plan
11. MassMutual Announces LEED-EB Certification Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology: